Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 4/20 | 0.40 |
| ▸ | HTR2A known ✓ | P28223 | 4/20 | 0.39 |
| ▸ | HTR2C known ✓ | P28335 | 4/20 | 0.39 |
| ▸ | HTR2B known ✓ | P41595 | 4/20 | 0.39 |
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A known ✓ | Q03164 | 1/20 | 0.38 |
| ▸ | JAK2 known ✓ | O60674 | 1/20 | 0.35 |
| ▸ | JAK1 known ✓ | P23458 | 1/20 | 0.35 |
| ▸ | TYK2 known ✓ | P29597 | 1/20 | 0.35 |
| ▸ | JAK3 known ✓ | P52333 | 1/20 | 0.35 |
| ▸ | GMNN | O75496 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL4122206 | 1.00 | DRD2 (0.40) | DRD2GMNNALDH1A1LMNAHPGD | |
| SCHEMBL13800099 | 0.93 | TGFBR1 (0.40) | DRD2ALDH1A1DRD4DRD3MEN1 | |
| Fumaric Acid SCHEMBL4132724 | 0.90 | DRD2 (0.43) | DRD2GMNNALDH1A1LMNAHPGD | |
| Fumaric Acid SCHEMBL4132722 | 0.90 | DRD2 (0.43) | DRD2GMNNALDH1A1LMNAHPGD | |
| SCHEMBL4110325 | 0.84 | BACE1 (0.41) | ALDH1A1TDP1SIGMAR1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL4115839 | 0.84 | BACE1 (0.40) | ALDH1A1TDP1SIGMAR1MEN1KMT2A | |
| SCHEMBL13800151 | 0.83 | BACE1 (0.44) | DRD2ALDH1A1LMNADRD4DRD3 | |
| Hydrochloric Acid SCHEMBL4127582 | 0.83 | BACE1 (0.43) | DRD2ALDH1A1LMNADRD4DRD3 | |
| SCHEMBL13800770 | 0.83 | HTR7 (0.40) | DRD2DRD4DRD3SIGMAR1MEN1 | |
| SCHEMBL6328221 | 0.82 | HTR7 (0.46) | DRD2DRD4DRD3SIGMAR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090143430-A1 | ERYTHROPOIETIN PRODUCTION ACCELERATOR | KOWA CO., LTD. (JP) | 2009-06-04 | — | — | US | disclosed |
| US-20060040986-A1 | Erythropoietin production accelerator | KOWA CO., LTD. (JP) | 2006-02-23 | — | — | US | disclosed |
| EP-1568691-A1 | ERYTHROPOIETIN PRODUCTION ACCELERATOR | Kowa Co., Ltd. (JP) | 2005-08-31 | — | — | EP | disclosed |
| US-20050176764-A1 | Medicine for treating cancer | KOWA CO., LTD (JP) | 2005-08-11 | — | — | US | disclosed |
| US-6867221-B2 | Cyclic amine compounds and pharmaceutical composition containing the same | KOWA CO., LTD. (JP) | 2005-03-15 | — | — | US | disclosed |
| EP-1422219-A1 | CYCLIC AMINE COMPOUND | Kowa Co., Ltd. (JP) | 2004-05-26 | — | — | EP | disclosed |
| US-20040010147-A1 | Cyclic amine compounds and pharmaceutical composition containing the same | KOWA CO., LTD. (JP) | 2004-01-15 | — | — | US | disclosed |
| US-6605620-B1 | Such as 4-(N-(4-Methoxyphenyl)-N-(3-(3,4,5-trimethoxy-phenyl)-benzoylamino)-1-((2 -(3,4,5-trimethoxyphenyl)pyridin-4-yl)-methyl)piperidine; treatment and prevention of cell adhesion or infiltration | KOWA CO., LTD. (JP) | 2003-08-12 | — | — | US | disclosed |
| US-6498169-B1 | CELL ADHESION AND INFILTRATION INHIBITORS; ANTIASTHMATICS, ANTIALLERGENS, ANTIRHEUMATICS, ANTIARTERIOSCLEROTICS, ANTIINFLAMMATORIES AND ANTI SJOGREN'S SYNDROME AGENTS | KOWA CO., LTD. (JP) | 2002-12-24 | — | — | US | disclosed |
| US-6395753-B1 | ANTIHISTAMINES, ANTIALLERGENS, ANTIARTHRITIC AGENTS | KOWA CO., LTD. (JP) | 2002-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176764-A1 | Medicine for treating cancer | HDAC4, HDAC3, NR4A3 | DRD2 2897/4885HTR2A 2298/4885HTR2C 1805/4885 |
| US-20060040986-A1 | Erythropoietin production accelerator | EPOR, GHRHR, ARL1 | DRD2 2405/4885HTR2A 4173/4885HTR2C 4146/4885 |
| US-20090143430-A1 | ERYTHROPOIETIN PRODUCTION ACCELERATOR | EPOR, GHRHR, ARL1 | DRD2 2405/4885HTR2A 4173/4885HTR2C 4146/4885 |
| US-20040010147-A1 | Cyclic amine compounds and pharmaceutical composition containing the same | HRH3, HRH4, CNKSR1 | DRD2 1366/4885HTR2A 1085/4885HTR2C 1188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.